Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT
| Autor: | Giancarlo Viberti, William H. Herman, Bernard Zinman, Steven E. Kahn, Steven M. Haffner, Gitanjali Paul, Rury R. Holman, John M. Lachin, Barbara G. Kravitz, R. Paul Aftring |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Urology Type 2 diabetes Pathophysiology Rosiglitazone Glibenclamide Insulin resistance Insulin-Secreting Cells Internal medicine Diabetes mellitus Glyburide Internal Medicine Humans Hypoglycemic Agents Medicine Aged Glycemic business.industry Insulin Middle Aged medicine.disease Metformin Endocrinology Diabetes Mellitus Type 2 Female Thiazolidinediones Insulin Resistance business medicine.drug |
| Zdroj: | Diabetes |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db10-1392 |
| Popis: | OBJECTIVE ADOPT (A Diabetes Outcome Progression Trial) demonstrated that initial monotherapy with rosiglitazone provided superior durability of glycemic control compared with metformin and glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine measures of β-cell function and insulin sensitivity from an oral glucose tolerance test (OGTT) over a 4-year period among the three treatments. RESEARCH DESIGN AND METHODS Recently diagnosed, drug-naïve patients with type 2 diabetes (4,360 total) were treated for a median of 4.0 years with rosiglitazone, metformin, or glyburide and were examined with periodic metabolic testing using an OGTT. RESULTS Measures of β-cell function and insulin sensitivity from an OGTT showed more favorable changes over time with rosiglitazone versus metformin or glyburide. Persistent improvements were seen in those who completed 4 years of monotherapy and marked deterioration of β-cell function in those who failed to maintain adequate glucose control with initial monotherapy. CONCLUSIONS The favorable combined changes in β-cell function and insulin sensitivity over time with rosiglitazone appear to be responsible for its superior glycemic durability over metformin and glyburide as initial monotherapy in type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|